Published 2 days ago • loading... • Updated 13 hours ago

AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere

MADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli Lilly and Bayer. ...

4 Articles

STAT

Center

At ESMO, AstraZeneca’s cancer pursuits get a showcase

Four of the conference's 12 presidential presentations featured drugs from AstraZeneca, with the spotlight on medicines both old and new.

1 day ago·Boston, United States

Read Full Article

Dagens industri

Astra Zeneca Presents Results From Several Cancer Studies

The pharmaceutical company Astra Zeneca has presented data from several different studies during the Esmo cancer congress in Madrid, Spain, over the weekend. This is evident from several press releases from the company.

13 hours ago

Read Full Article

privataaffarer.se

Astra Zeneca Presented Data From Several Studies

The pharmaceutical company Astra Zeneca has presented data from several different studies during the Esmo cancer congress in Madrid over the weekend, according to several press releases from the company.

13 hours ago

Read Full Article

endpoints.news

AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources4

Leaning Left0Leaning Right0Center1Last Updated13 hours agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news 2 days ago on Saturday, October 24, 2026.

Sources are mostly out of (0)

AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere

4 Articles

4 Articles

At ESMO, AstraZeneca’s cancer pursuits get a showcase

Astra Zeneca Presents Results From Several Cancer Studies

Astra Zeneca Presented Data From Several Studies

AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 ...

AstraZeneca’s stomach cancer drug clears bar for extending overall survival in late-stage study

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® Plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Attackers kill nurse, severely injure health worker responding to Ebola case in eastern Congo

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

NHS consultants to go on two-day strike in England in November, says BMA

Similar News Topics

Similar News Topics

More stories like this

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 ...

AstraZeneca’s stomach cancer drug clears bar for extending overall survival in late-stage study

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® Plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Attackers kill nurse, severely injure health worker responding to Ebola case in eastern Congo

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

NHS consultants to go on two-day strike in England in November, says BMA

AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere

4 Articles

4 Articles

At ESMO, AstraZeneca’s cancer pursuits get a showcase

Translate IconAstra Zeneca Presents Results From Several Cancer Studies

Translate IconAstra Zeneca Presented Data From Several Studies

AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 ...

AstraZeneca’s stomach cancer drug clears bar for extending overall survival in late-stage study

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® Plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Attackers kill nurse, severely injure health worker responding to Ebola case in eastern Congo

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

NHS consultants to go on two-day strike in England in November, says BMA

Similar News Topics

Similar News Topics

More stories like this

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 ...

AstraZeneca’s stomach cancer drug clears bar for extending overall survival in late-stage study

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® Plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Attackers kill nurse, severely injure health worker responding to Ebola case in eastern Congo

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

NHS consultants to go on two-day strike in England in November, says BMA

Astra Zeneca Presents Results From Several Cancer Studies

Astra Zeneca Presented Data From Several Studies

Bias Distribution

Factuality